|
|
|
|
 |
|||
|
|||
Originally published as JHC exPRESS on August 22, 2005.
doi:10.1369/jhc.5A6645.2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Volume 54 (1): 63-73, 2006
Copyright ©The Histochemical Society, Inc.
Expression of Serum Amyloid A, in Normal, Dysplastic, and Neoplastic Human Colonic Mucosa: Implication for a Role in Colonic Tumorigenesis
Hematology Unit (SU-S,SD,ML), Departments of Oncology (OG), Pathology (DP), and Internal Medicine (ZA), Hadassah-Hebrew University Medical Center, Mount Scopus and Ein-Kerem, Jerusalem, Israel, and the Max-Planck-Institut für Biochemie, Martinsried, Germany (RPL)
Correspondence to: Simcha Urieli-Shoval, Hematology Unit, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem 91240, Israel. E-mail: simcha{at}hadassah.org.il
 |
Summary |
|---|
 Top Summary IntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
Serum amyloid A (SAA) is an acute phase reactant, whose level in the blood is elevated in response to trauma, infection, inflammation, and neoplasia. Elevated levels of SAA in the serum of cancer patients were suggested to be of liver origin rather than a tumor cell product. The role of SAA in human malignancies has not been elucidated. We investigated the expression of SAA at various stages of human colon carcinoma progression. Nonradioactive in situ hybridization applied on paraffin tissue sections from 26 colon cancer patients revealed barely detected SAA mRNA expression in normal looking colonic epithelium. Expression was increased gradually as epithelial cells progressed through dysplasia to neoplasia. Deeply invading colon carcinoma cells showed the highest levels of SAA. Expression was also found in colon carcinoma metastases. Cells of lymphoid follicles of the intestinal wall, inflammatory cells, ganglion cells, and endothelial cells, also expressed SAA mRNA. Immunohistochemical staining revealed SAA protein expression that colocalized with SAA mRNA expression. RT-PCR analysis confirmed the expression of the SAA1 and SAA4 genes in colon carcinomas, expression that was barely detectable in normal colon tissues. These findings indicate local and differential expression of SAA in human colon cancer tissues and suggest its role in colonic tumorigenesis. (J Histochem Cytochem 54:63–73, 2006)
Key Words: serum amyloid A • colon tissues • colonic neoplasia
|
Introduction |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
SERUM AMYLOID A (SAA), an HDL-associated apolipoprotein, is an acute phase protein whose level in the blood is elevated up to 1000-fold in response of the body to various injuries including trauma, various inflammations, and neoplasia (Urieli-Shoval et al. 2000
). As for other acute phase proteins, the liver is the major site of SAA expression. Extrahepatic SAA expression was described in human atherosclerotic lesions (Meek et al. 1994), in the brain of Alzheimer disease patients (Liang et al. 1997), in synovial tissues from rheumatoid arthritis patients (Kumon et al. 1999), and in many histologically normal tissues, predominantly by their epithelium (Urieli-Shoval et al. 1998). SAA expression in malignant tissues has not been investigated.
SAA levels were found to be elevated in the serum of patients with a wide range of malignancies, being highest in those with metastatic carcinoma of unknown primary sites (Rosenthal and Sullivan 1979). SAA levels are significantly higher in patients with distant metastases as compared with those with localized disease. The levels are inversely correlated with patient's survival (Weinstein et al. 1984; Biran et al. 1986) and are decreased in response to therapy (Kaneti et al. 1984). Based on these findings SAA was suggested as a marker for neoplastic activity. More recently, using modern mass spectrometry and proteomic technologies, SAA was identified as the most significant protein differentiating the serum of patients with lung cancer from the serum of healthy individuals (Howard et al. 2003) and as a protein whose serum level strongly correlates with the clinical relapse status in nasopharyngeal cancer patients (Cho et al. 2004). In colon cancer patients, SAA levels, when compared with levels of other acute phase proteins including C-reactive protein, showed the best specificity and sensitivity to disease activity (Glojnaric et al. 2001). The SAA protein in the serum of cancer patients, in both the old and the more recent studies, was suggested to be of liver origin, rather than being produced locally in the tumor tissue.
Despite the four decades of research since its first recognition as the precursor protein in inflammation-associated AA amyloidosis (Benditt et al. 1962; Levin et al. 1973; Linke et al. 1975), the biological importance of SAA in health and disease is not well understood. Today SAA is viewed as a multifunctional protein playing a role mainly as a modulator of inflammatory processes and being involved in cholesterol metabolism and transport (Urieli-Shoval et al. 2000). The mode of involvement of SAA in human malignancies has not been elucidated. However, several functions of the SAA protein, described in the context of inflammation, are compatible with the mechanism of tumor cell invasion and metastasis. These include: induction of cell adhesion and migration (Badolato et al. 1994; Xu et al. 1995; Preciado-Patt et al. 1996; Hershkoviz et al. 1997), induction of enzymes degrading the extracellular matrix (ECM) (Migita et al. 1998; O'Hara et al. 2004), and inhibition of cell attachment to ECM proteins by SAA-derived peptides (Preciado-Patt et al. 1994). Furthermore, SAA contains binding sites for the ECM constituents laminin (Ancsin and Kisilevsky 1999a) and heparin/heparan sulfate (Ancsin and Kisilevsky 1999b), it complexes with native ECM and ECM proteins (Preciado-Patt et al. 1996; Hershkoviz et al. 1997) and has functional arginine-glycine-aspartic acid (RGD)-like and tyrosine-isoleucine-glycine-serine-arginine (YIGSR)-like adhesion motifs (Linke et al. 1991; Preciado-Patt et al. 1994; Urieli-Shoval et al. 2002). Cumulatively, these properties place SAA as an ECM-associated adhesion protein, with a potential role in tumor pathogenesis.
Because of the elevation of serum SAA levels in cancer patients and because of the adhesion functions of SAA protein, we felt it was important to directly evaluate the expression of SAA in human cancerous tissues. The main focus of this study was to document, by in situ hybridization, SAA gene expression in colon tissues from normal-looking colonic mucosa through adenoma with different grades of dysplasia to invasive carcinoma and metastases.
Immunohistochemistry and RT-PCR analyses were used on selected tissues to verify that the expression demonstrated by in situ hybridization accurately portrays SAA gene expression and SAA protein synthesis. We demonstrate that the SAA mRNA and protein are locally expressed in human colon carcinoma tissues, predominantly by the tumor cells. Furthermore, we found that SAA mRNA expression in epithelial cells increases gradually as they progress through different stages of dysplasia to overt carcinoma.
|
Materials and Methods |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
Tissues
Conventional serial sections of routinely processed formalin-fixed and paraffin-embedded archival tissues from 26 patients with colonic neoplasia operated between 1999 and 2004 were obtained from the Department of Pathology, Hadassah-Hebrew University Medical Center, Mount Scopus. The demographics and histological grading and staging of the colon cancer patients; the type of sections included in the study are detailed in Table 1. The sections included: 25 sections of colon adenocarcinomas, 10 sections of metastases; 8 to regional lymph nodes, 1 to liver, and 1 to omentum; and 11 sections of adenomatous polyps and 18 sections of normal looking colonic epithelium taken from surgical margins. Sections of a liver were used as positive controls. Freshly frozen biopsies of colon adenocarcinomas, as well as normal colons, from 3 patients (patients 2, 8, and 9 in Table 1), were obtained from the Department of Pathology. Studies were approved by the Human Subjects Research Committee of the Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
|
Probes
The SAA probe was prepared from pGEM transcription vector that contained a 110-bp sequence of mouse SAA1 cDNA (p125) (Meek and Benditt 1989
). This nucleotide sequence encompasses a domain coding for amino acid residues 30–66 that is highly conserved among species and is highly homologous with human SAA genes, as described previously (Meek et al. 1994). To generate digoxigenin labeled probe, p125 was linearized with HindIII (antisense) or EcoRI (sense) and incubated in a transcription reaction containing 500 µM each of GTP, ATP, and CTP (Promega Biotec; Madison, WI) and 500 µM digoxigenin-labeled UTP (Boehringer-Mannheim; Indianapolis, IN) as described (Urieli-Shoval et al. 1992;1998). In addition to the sense control probes, nonlabeled antisense probes were generated by including UTP instead of digoxigenin-labeled UTP, in the transcription reaction.
In Situ Hybridization
Nonradioactive in situ hybridization was performed as previously described (Urieli-Shoval et al. 1992;1998) with slight modifications. Deparaffinized and rehydrated sections were digested with proteinase K (5 µg/ml, 40 min, 37C) and prehybridized in 100 µl hybridization buffer (50% deionized formamide/0.3 M NaCl/20 mM Tris-HCl, pH 8.0/5 mM EDTA/1 x Denhardt's/10% dextran sulfate) for 2 hr at 50C. Hybridization was initiated by addition of 50 µl hybridization buffer containing the labeled antisense probe and was allowed to proceed for 15–18 hr at 50C. Parallel sections were incubated with either the sense probe or the antisense probe mixed with a 20-fold excess of nonlabeled antisense probe, to be used as negative controls. Liver sections were used as positive controls. After hybridization the sections were treated with RNase A (20 µg/ml, 30 min, room temperature), followed by 0.1 x SSC/0.5% Tween 20 (3 x 40 min, 37C), and proceeded with the immunodetection, which was accomplished with the Genius Nonradioactive Nucleic Acid Detection Kit (Boehringer-Mannheim) with modifications. Slides were incubated in 100 mM Tris HCl, pH 8.0/150 mM NaCl (buffer 1) containing 2% normal sheep serum and 0.3% Triton-X-100 at room temperature for 30 min. One hundred ml of anti-digoxigenin antibody conjugated to alkaline phosphatase (1:1000 dilution in buffer 1 containing 1% normal sheep serum and 0.3% Triton X-100) was applied onto the slides, which were incubated in a humid chamber overnight at 4C. After washing in buffer 1, a color solution (alkaline phosphate substrate kit III; Vector Laboratories, Burlingame, CA) was applied onto the slides and incubation was carried out at room temperature in a dark chamber until a satisfying intensity of color developed (usually 60 min). Sections were counterstained with acridine orange/safranin O (Urieli-Shoval et al. 1992;1998). The intensity of staining was graded by a trained pathologist (DP) using a three-point scale: negative (0), weak (1), and moderate to strong (2 to 3).
Immunohistochemistry
Immunohistochemistry was performed using the Histostain Plus SP kit which offers superior sensitivity (Zymed Laboratories Inc.; San Francisco, CA). Briefly, deparaffinized and rehydrated sections were digested with protease (0.1% in PBS, 15 min, room temperature) and then treated according to the manufacturer instructions using the ready-to-use kit components. Two anti-SAA monoclonal antibodies were used: clone mcl (DAKO Corporation; Carpinteria, CA), was directed against AA-amyloid fibril protein and detecting also SAA and clone mc29, directed against the highly conserved (invariant) region of SAA. The preparation and specificity of these antibodies were previously described and demonstrated (Linke 1984; Linke et al. 1991). The specificity of clone mc29, as assessed by Western blotting, as well as its neutralizing activity were demonstrated recently again (Urieli-Shoval et al. 2002). Antibodies were diluted 1:20 (mc1) and 1:600 (mc29) in 0.1 M Tris-HCl pH 7.6 and incubation lasted 2 hr at room temperature. Color was developed using AEC substrate (Zymed Laboratories Inc.) for 10 min followed by counterstaining with hematoxylin. Negative controls included replacement of the primary antibodies by PBS and by normal mouse isotype–matched IgG (IgG2a, kappa; DAKO Corporation). Liver sections were used as positive controls.
RT-PCR
Total RNA was extracted from tissue sections cut from formalin-fixed paraffin-embedded blocks using Paraffin Block RNA Isolation Kit (Ambion; Austin, TX). RNA was also extracted from freshly frozen tissue biopsies using Tri Reagent (Molecular Research Center; Cincinnati, OH). Synthesis of cDNA was performed using random hexamer primer and the SuperScript II RNase H– reverse transcriptase (Invitrogen Life Technologies; Paisley, UK). Amplification of cDNA was done using Supertherm DNA polymerase (JMR Holdings; London, UK) and primers specific for each of the four known human SAA genes; SAA1, SAA2, SAA3, and SAA4. The sequence of the primers and their specificity were previously described (Urieli-Shoval et al. 1994). Amplification of a fragment of the housekeeping gene ß-actin (220 base pairs) was used as a positive control for successful amplification of the cDNA, using primers previously described (Kaneko-Ishino et al. 1995). Negative controls included replacement of the cDNA mixture with H2O in the PCR reaction. Mixtures were incubated in a thermocycler (MJ Research Inc.; Watertown, MA) under the following conditions: 1 cycle of 2 min at 95C followed by 40 cycles each consisting of 30 sec at 95°C, 30 sec at 59°C, and 30 sec at 72C and at the end followed by 1 cycle of 2 min at 72C. The identity of the PCR amplification products was confirmed by their sequencing using the SAA primers and the BigDye Terminator cycle sequencing chemistry from Applied Biosystems (Foster City, CA). Sequencing was carried out on an automated DNA sequencer (Model 3700 DNA Analyzer; Applied Biosystems), in the center for genomic technologies, the Hebrew University, Jerusalem, Israel.
|
Results |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
In Situ Hybridization and Immunohistochemistry of Human Colon Tissues
We applied the nonradioactive in situ hybridization technique, on human colon tissue sections from 26 colon cancer patients (as detailed in Table 1), to determine whether human colon tissues express SAA mRNA, what cell types are responsible for such an expression, and whether SAA is differentially expressed in the progressive stages of human colon carcinoma. Two controls were used for nonspecific hybridization: the sense probe and the antisense probe mixed with a 20-fold excess of nonlabeled antisense probe, both resulted with diminished signal. Liver sections used as positive controls and showed positive staining of hepatocytes, as described (Urieli-Shoval et al. 1998
). Our findings are described in the following section. We applied immunohistochemistry on selected sections, as detailed in Table 1, to document that the presence of SAA mRNA is accompanied by SAA protein synthesis. Two different anti-SAA monoclonal antibodies were used, resulting with a similar pattern of staining. Negative controls included replacement of the primary antibody by either PBS or normal mouse isotype-matched IgG, both resulting in diminished signal. Liver sections used as positive controls and hepatocytes were positively stained with anti-SAA antibody but not with control IgG (Figures 2G and 2H).
|
The following is a description of our findings.
Normal Colonic Epithelium
Eighteen sections of normal mucosa obtained from surgical margins and 12 sections of primary tumors that included also normal-looking colonic epithelium adjacent to the neoplastic tissue were stained for SAA mRNA by in situ hybridization. In 22 of 30 sections (73.3%) the normal epithelium did not stain; a representative result is demonstrated in Figures 1A
and 1B. In a few sections (6 of 30) focal and weak staining for SAA mRNA was found on the surface epithelium and occasionally on the crypt epithelium. In only 2 of the 30 sections studied, was there a diffuse strong staining of the normal epithelium. Cells in lymphoid follicles of the intestinal wall (Figure 1A), lymphoplasmacytic infiltrate of the submucosa (Figure 1B), ganglion cells, and occasional endothelial cells were also positively stained. Fibroblasts in the stroma were negative. Immunohistochemistry revealed weak cytoplasmic staining of SAA protein in the surface epithelium (not shown).
|
Polyps
Eleven adenomatous polyp sections, from 11 distinct polyps, were stained for SAA mRNA by in situ hybridization. In 4 of 11 sections (36%) the epithelium was not stained. In 7 of the 11 sections, weak (2 sections) to moderate (5 sections) staining for SAA mRNA was found in the dysplastic epithelium (Figures 1C and 1D). In some sections, there was correlation between the staining intensity and the histologic grade (i.e., low-grade dysplastic cells were negative or faintly labeled, whereas high-grade dysplastic cells were heavily labeled) (Figure 1D). However, this was not the rule in all sections. In the adjacent normal-looking epithelium, there was occasionally weak staining of the surface epithelium. Cells in lymphoid follicles, inflammatory cells, and ganglion cells, when present, were positively stained as well. Immunohistochemistry revealed intense cytoplasmic staining of the SAA protein in dysplastic cells (Figure 2A ) and in inflammatory cells.
Primary Tumors
Twenty-five sections of primary tumors, ranging from well to poorly differentiated carcinoma, were stained for SAA mRNA by in situ hybridization. In all the sections, strong cytoplasmic staining was found in the malignant epithelial cells (Figures 1E and 1F). In 10 of the 25 sections, stronger and more diffuse staining was observed in deeply invading tumor cells as compared with the more superficial neoplastic glands, which showed weaker and sometimes only apical staining. This finding suggests a positive correlation between staining intensity and depth of invasion. Nevertheless, there was no difference in staining intensity between tumors from patients with different stages of colon cancer or tumors of different histologic grades. In desmoplastic regions, SAA staining was noted also in the stromal fibroblasts and in endothelial cells (Figure 1G). Lymphocytes and ganglion cells (Figure 1H) were positively stained as well. Immunohistochemistry revealed diffuse cytoplasmic SAA protein staining in malignant epithelial cells (Figure 2C) and in inflammatory cells, endothelial cells, and fibroblasts in desmoplastic regions. Extracellular staining was also observed (not shown).
Metastases
In 9 of the 10 sections stained by in situ hybridization of metastases to regional lymph nodes (Figure 1I), liver, or omentum, moderate to strong SAA mRNA staining was found in the majority of the malignant epithelial cells. However, staining was somewhat weaker compared with the primary tumors. Cells in germinal centers in lymph nodes stained positive as well (Figure 1I). Immunohistochemistry revealed diffuse cytoplasmic staining for SAA protein in the metastasizing colon carcinoma cells (Figure 2E); staining was somewhat weaker compared with the primary tumors. Staining was observed also in cells of germinal centers of lymph nodes (not shown).
RT-PCR Analysis of Human Colon Tissues
We carried out RT-PCR analysis on RNA extracted from sections cut from paraffin blocks participating in this study to further support the in situ hybridization findings and to determine which of the four known human SAA genes are expressed. Oligonucleotide primers specific for each of the four known human SAA genes—SAA1, SAA2, SAA3, and SAA4—were used. In Figure 3A
, results obtained from tumor sections of patient 21 in Table 1 are shown. Fragments of the predicted sizes were amplified when the SAA1- and SAA4-specific primers were used and no PCR products were obtained for the SAA2 and SAA3 genes. The identity of the PCR products was confirmed by their sequencing and comparison to SAA sequences reported in the GenBank/EMBL Databases. The colon-derived SAA1 sequence had 99% nucleotide homology with clones with the accession numbers NM 000331 and NM 199161. The colon-derived SAA4 sequences had 99% nucleotide homology with clone with the accession number M81349. Similar results were obtained applying this analysis on tumor sections of patient 15 in Table 1 (not shown).
|
We also performed RT-PCR on RNA extracted from freshly frozen tumor and normal colon biopsies, from three patients (patients 2, 8, and 9 in Table 1). In Figure 3B, the SAA1 and SAA4 genes are strongly expressed in the tumor tissues, whereas their expression is weak to barely detectable in the normal tissues obtained from the same patients. The control gene ß-actin is expressed at equal levels in both the tumor and the normal samples.
|
Discussion |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
High levels of SAA in the serum of cancer patients, including colon cancer patients, were suggested to be of liver origin. Expression of SAA in tumor tissues has not been investigated and its role in human malignancies has not been elucidated. In the present study, using nonradioactive in situ hybridization, immunohistochemistry, and RT-PCR analyses, we demonstrate local expression of SAA mRNA and protein in human colon adenocarcinomas. We found that the tumor cells are the predominant SAA expressing cells. Moreover, the SAA mRNA expression in epithelial cells is gradually increased as they progress through different stages of dysplasia to overt carcinoma. Local and differential expression of SAA in human colon cancer tissues suggests its role in colonic tumorigenesis and may have both prognostic and therapeutic applications.
In most of the normal-looking colonic epithelium, no SAA mRNA was detected and in the few sections in which some staining was observed, it was weak and confined to the surface epithelium. In only two sections, was there a diffuse strong staining of the normal epithelium. In adenomatous polyps, weak to moderate staining for SAA mRNA was found in the dysplastic epithelium and more so in the severely dysplastic cells. In all sections of colon adenocarcinomas, there was strong diffuse cytoplasmic staining for SAA mRNA in the tumor cells. In about half of the sections, stronger and more diffuse staining was found in deeply invading tumor areas as compared with the more superficial tumor glands. In the metastases studied, there was expression of SAA mRNA in almost all the sections studied; however, staining was somewhat weaker compared with the primary tumors. These results, which are summarized in Figure 4 , indicate positive correlation between epithelial SAA mRNA expression and the progressive stages of colonic neoplasia. Post hoc comparison of the four groups (Tukey) showed that normal epithelium stained significantly different from staining of dysplastic polyp epithelium, primary tumor, and metastatic epithelium. Staining of dysplastic polyp epithelium was significantly different from staining of primary tumor and metastatic epithelium. There was no significant difference in staining between the primary tumor epithelium and the metastatic epithelium.
|
Immunohistochemistry experiments revealed SAA protein expression that colocalized with mRNA expression. Cytoplasmic staining in dysplastic, neoplastic, and metastatic epithelial cells was observed. Colocalization of SAA mRNA and protein was found also in stromal elements including inflammatory cells, endothelial cells, and fibroblasts, predominantly in desmoplastic areas. In addition to cell-associated protein staining, there was also extracellular staining mainly in the primary tumor sections. This staining presumably represents SAA bound to the extracellular matrix, because SAA binds to extracellular matrix proteins, as revealed by in vitro studies (Preciado-Patt et al. 1996
; Hershkoviz et al. 1997). Extracellular immunostaining could be derived not only from locally synthesized protein but could also represent liver-derived SAA arriving from the blood and diffused into the tissue.
The human SAA gene family comprises four discrete loci containing two highly homologous genes, SAA1 and SAA2, and two less related genes, SAA3 and SAA4. SAA1 and SAA2 corresponding proteins are the predominant circulating SAA proteins during the acute phase response (Betts et al. 1991; Uhlar et al. 1994). The SAA3 gene was considered a nonexpressed gene (Kluve-Beckerman et al. 1991), but recently its expression was demonstrated in mammary epithelial cells (Larson et al. 2003). The gene for SAA4 is constitutively expressed and its protein product is a constituent of normal, nonacute phase, high-density lipoprotein (Whitehead et al. 1992). Expression of the genes SAA1, SAA2, and SAA4 can be induced in human cultured smooth muscle cells (Meek et al. 1994) and in human monocyte/macrophage cell lines (Urieli-Shoval et al. 1994). Constitutive expression of SAA4 and inducible expression of SAA1 and SAA2 genes in some human carcinoma cell lines was demonstrated (Steel et al. 1996). Here we show that human colon carcinomas express the SAA1 and SAA4 genes, as revealed by RT-PCR analysis of paraffin sections and freshly frozen tissues. RT-PCR also revealed that these genes are preferentially expressed in carcinomas as compared with normal colons, consistent with the preferential staining observed by in situ hybridization.
Was the SAA transcript identified in molecular studies looking for differentially expressed genes in human cancer? Using serial analysis of gene expression (SAGE), SAA was found among 548 differentially expressed genes in human neoplastic vs normal gastrointestinal tissues (Zhang et al. 1997). In another SAGE analysis, SAA was found among three genes whose expression is reduced in metastatic as compared with primary colon tumor cell lines (Parle-McDermott et al. 2000). This reduced expression is in line with the weaker staining of the metastasizing colon adenocarcinoma cells compared with the primary tumor, as found in our study. SAGE analysis also identified SAA among 13 genes, all oxidative stress-related genes, whose expression is markedly increased in p53-infected colorectal cancer cell line (Polyak et al. 1997). Finally, using suppression subtractive hybridization, SAA was identified among nine genes whose expression is increased in renal cell carcinoma compared with surrounding renal tissue (Nishie et al. 2001). The significance of the dif ferential expression of SAA, as found in these studies, to human cancer is not yet known.
Although the role of SAA expressed in human colon cancer tissues is not known at present, several proposed functions for the SAA protein could be relevant to the mechanism of tumor cell invasion and metastasis: (1) SAA may serve as an adhesive ligand for tumor cells as has been shown for human lymphocytes (Badolato et al. 1994; Xu et al. 1995; Preciado-Patt et al. 1996), mast cells (Hershkoviz et al. 1997), platelets, and certain melanoma cells (Urieli-Shoval et al. 2002); (2) SAA may induce the migration of tumor cells to the perivascular tissue toward metastases sites, because it induces the migration and tissue infiltration of lymphocytes (Badolato et al. 1994; Xu et al. 1995) and vascular muscle cells (Kumon et al. 2002); (3) SAA may influence tumor cell invasion through the extracellular matrix because it induces matrix metalloproteinases (Migita et al. 1998; O'Hara et al. 2004); (4) SAA-derived peptides may inhibit tumor cell attachment to proteins of the extracellular matrix, as has been shown for T-lymphocytes and platelets (Preciado-Patt et al. 1994; Urieli-Shoval et al. 2002); (5) SAA may play a role in p53-induced apoptosis, as was suggested based on its identification as an induced gene in this system (Polyak et al. 1997), the mechanism by which is not yet known; and (6) in light of recent studies revisiting the concept of inflammation-associated tumorigenesis (Balkwill and Mantovani 2001; Pikarsky et al. 2004; Clevers 2004), SAA may play a role in the local inflammation in the microenvironment of the malignant tissue. SAA may not only induce the migration and tissue infiltration of inflammatory cells (Badolato et al. 1994; Xu et al. 1995) in the tumor mass, but may also induce the production of pro-inflammatory cytokines; tumor necrosis factor-
, interleukin-1ß, and interleukin-8 (Patel et al. 1998; Furlaneto and Campa 2000). Whether any of these possibilities have relevance in the development of human colon cancer, or other cancers, requires further investigation.
Finally, to our knowledge, this is the first systematic study describing expression of SAA in human colon cancer tissues or any malignant tissue. Also we have shown preferential expression of the SAA mRNA and protein in colon tumors as compared with the normal-looking colonic epithelium. It is not known whether the SAA produced in the cancerous tissues is secreted and contributes to the elevated SAA levels in the serum of cancer patients. Alternatively, the tumor may secrete mediators that stimulate SAA synthesis in the liver resulting in high SAA serum levels, as has been suggested (Ghezzi et al. 1993). Future prospective study investigating the correlation of SAA serum levels with expression in tissues from the same patients may help clear this issue.
|
Acknowledgments |
|---|
Supported by the Israel Cancer Research Fund and the Israel Science Foundation (no. 686/00-1) (to SU-S), the Deutsche Forschungsgemeinschaft, Bonn, Germany (Li 247/12-3), and the courtesy of Prof. R. Huber, Max-Planck-Institute of Biochemistry, Martinsried, Germany (to RPL).
We wish to dedicate this article to the memory of Prof. Yaacov Matzner, the Head of the Hematology Unit, who died tragically in a plane crash on November 24, 2001. His wisdom, encouragement, and scientific legacy continue to inspire us in this study and the research projects in general. We thank R.L. Meek (the Heart Institute of Spokane) for the p125 clone.
|
Footnotes |
|---|
1 These authors share first authorship.
Received for publication February 3, 2005; accepted August 1, 2005
|
Literature Cited |
|---|
|
TopSummaryIntroductionMaterials and MethodsResultsDiscussionLiterature Cited |
|---|
Ancsin JB, Kisilevsky R (1999a) Laminin interactions with the apoproteins of acute-phase HDL: preliminary mapping of the laminin binding site on serum amyloid A. Amyloid:Int J Exp Clin Invest 6:37–47
Ancsin JB, Kisilevsky R (1999b) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274:7172–7181
Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, Bausserman LL, Kelvin DJ, et al. (1994) Serum amyloid A is a chemoattractant: induction of migration, adhesion and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180:203–209
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? The Lancet 357:539–545
Benditt EP, Lagunoff D, Eriksen N, Iseri OA (1962) Amyloid. Extraction and preliminary characterization of some proteins. Arch Pathol 74:323–330[Medline]
Betts JC, Edbrooke MR, Thakker R, Woo P (1991) The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand J Immunol 34:471–482[CrossRef][Medline]
Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39:794–797
Cho WCS, Yip TTC, Yip C, Yip V, Thulasiraman V, Ngan RKC, Yip T-T, et al. (2004) Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10:43–52
Clevers H (2004) At the crossroads of inflammation and cancer. Cell 118:671–674[CrossRef][Medline]
Furlaneto CJ, Campa A (2000) A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 268:405–408[CrossRef][Medline]
Ghezzi P, Bertini R, Bianchi M, Erroi A, Mengozzi M, Delgado R, Giavazzi R, et al. (1993) Serum amyloid A induction in tumor-bearing mice: evidence for a tumor-derived mediator. Int J Immunopathol Pharmacol 6:169–186
Glojnaric I, Casl MT, Simic D, Lukac J (2001) Serum amyloid A (SAA) in colorectal carcinoma. Clin Chem Lab Med 39:129–133[CrossRef][Medline]
Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (2002). The American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. New York, Springer-Verlag
Hershkoviz R, Preciado-Patt L, Lider O, Fridkin M, Dastych J, Metcalfe DD, Mekori YA (1997) Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Am J Physiol 273:179–187
Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF (2003) Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3:1720–1724[CrossRef][Medline]
Kaneko-Ishino T, Kuroiwa Y, Miyoshi N, Kohda T, Suzuki R, Yokoyama M, Viville S, et al. (1995) Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. Nat Genet 11:52–59[CrossRef][Medline]
Kaneti J, Winikoff Y, Zimlichman S, Shainkin-Kestenbaum R (1984) Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol Res 12:239–241[Medline]
Kluve-Beckerman B, Drumm ML, Benson MD (1991) Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell Biol 10:651–661[Medline]
Kumon Y, Hosokawa T, Suehiro T, Ikeda Y, Sipe JD, Hashimoto K (2002) Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid 9:237–241[Medline]
Kumon Y, Suehiro T, Hashimoto K, Nakatani K, Sipe JD (1999) Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J Rheumatol 26:785–790[Medline]
Larson MA, Wei SH, Weber A, Weber AT, McDonald TL (2003) Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem Biophys Res Commun 301:1030–1037[CrossRef][Medline]
Levin M, Pras M, Franklin EC (1973) Immunologic studies of the major nonimmunoglobulin protein of amyloid. Identification and partial characterization of a related serum component. J Exp Med 138:373–380[Abstract]
Liang JS, Sloane JA, Wells JM, Abraham CR, Fine RE, Sipe JD (1997) Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci Lett 225:73–76[CrossRef][Medline]
Linke RP (1984) Monoclonal antibodies against amyloid fibril protein AA. Production, specificity and use for immunohistochemical localization and classification of AA-type amyloidosis. J Histochem Cytochem 32:322–328[Abstract]
Linke RP, Bock V, Valet G, Rothe G (1991) Inhibition of the oxidative burst response of N formyl peptide-stimulated neutrophils by serum amyloid A protein. Biochem Biophys Res Comm 176: 1100–1105[CrossRef][Medline]
Linke RP, Sipe JD, Pollock PS, Ignaczak TF, Glenner GG (1975) Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin. Proc Natl Acad Sci USA 72:1473–1476
Meek RL, Benditt EP (1989) Rat tissues express serum amyloid A protein-related mRNAs. Proc Natl Acad Sci USA 86:1890–1894
Meek RL, Urieli-Shoval S, Benditt EP (1994) Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implication for serum amyloid A function. Proc Natl Acad Sci USA 91:3186–3190
Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K (1998) Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 78: 535–539[Medline]
Nishie A, Masuda K, Otsubo M, Migita T, Tsuneyoshi M, Kohno K, Shuin T, et al. (2001) High expression of the cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin Cancer Res 7:2145–2151
O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B (2004) Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 50:1788–1799[CrossRef][Medline]
Parle-McDermott A, McWilliam P, Tighe O, Dunican D, Croke DT (2000) Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br J Cancer 83:725–728[CrossRef][Medline]
Patel H, Fellowes R, Coade S, Woo P (1998) Human serum amyloid A has cytokine-like properties. Scan J Immunol 48:410–418[CrossRef][Medline]
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, et al. (2004) NF-
B functions as a tumor promoter in inflammation-associated cancer. Nature 431:461–466[CrossRef][Medline]
Polyak K, Xla Y, Zweler JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389:300–305[CrossRef][Medline]
Preciado-Patt L, Hershkoviz R, Fridkin M, Lider O (1996) Serum amyloid A binds specific extracellular matrix glycoproteins and induces the adhesion of resting CD4+ T cells. J Immunol 156: 1189–1195[Abstract]
Preciado-Patt L, Levartowsky D, Pras M, Hershkoviz R, Lider O, Fridkin M (1994) Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. Eur J Biochem 223:35–42[Medline]
Rosenthal CJ, Sullivan LE (1979) Serum amyloid A to monitor cancer dissemination. Ann Intern Med. 91:383–390
Steel DM, Donoghue FC, O'Neill RM, Uhlar CM, Whitehead AS (1996) Expression and regulation of constitutive and acute phase serum amyloid A mRNAs in hepatic and non-hepatic cell lines. Scan J Immunol 44:493–500[CrossRef][Medline]
Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS (1994) Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 19: 228–235[CrossRef][Medline]
Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y (1998) Widespread expression of serum amyloid A in histologically normal human tissues: predominant localization to the epithelium. J Histochem Cytochem 46:1377–1384
Urieli-Shoval S, Linke RP, Matzner Y (2000) Expression and function of serum amyloid A (SAA), a major acute phase protein, in normal and disease states. Curr Opin Hematol 7:64–69[CrossRef][Medline]
Urieli-Shoval S, Meek RL, Hanson RH, Eriksen N, Benditt EP (1994) Human serum amyloid A genes are expressed in monocyte/macrophage cell lines. Am J Pathol 145:650–660[Abstract]
Urieli-Shoval S, Meek RL, Hanson RH, Ferguson M, Gordon D, Benditt EP (1992) Preservation of RNA for in situ hybridization: Carnoy's versus formaldehyde fixation. J Histochem Cytochem 40:1879–1885
Urieli-Shoval S, Shubinsky G, Linke RP, Fridkin M, Tabi I, Matzner Y (2002) Adhesion of human platelets to serum amyloid A. Blood 99:1224–1229
Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS (1984) Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19:193–198[Medline]
Whitehead AS, deBeer MC, Steel DM, Rits M, Lelias JM, Lane WS, deBeer FC (1992) Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J Biol Chem 267:3862–3867
Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, Oppenheim JJ, Wang JM (1995) A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 155:1184–1190[Abstract]
Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, et al. (1997) Gene expression profiles in normal and cancer cells. Science 276:1268–1272
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Guidelines | Subscriptions | About | exPRESS - Current - Archive | Business Information | Contact |